Acute leukemia in a patient cured of diffuse histiocytic lymphoma.
A patient is described who, after completing treatment for diffuse histiocytic lymphoma, remained disease-free for 7 years (presumably cured), then developed acute nonlymphocytic leukemia (ANLL) after a brief preleukemic phase. Marrow cytogenetic analysis at the onset of frank leukemia revealed loss of chromosomes 5 and 7, which is consistent with secondary leukemia. She received only chemotherapy for her lymphoma, including high doses of an alkylating agent and a nitrosourea, which may have contributed to the development of the leukemia. This case report suggests that secondary ANLL may complicate the course of some long-term disease-free survivors of diffuse histiocytic lymphoma.
D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D001761:Bleomycin / Q000627:therapeutic use; D002872:Chromosome Deletion; D002905:Chromosomes, Human, 4-5; D002906:Chromosomes, Human, 6-12 and X; D003520:Cyclophosphamide / Q000009:adverse effects; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007938:Leukemia / Q000209:etiology* / Q000235:genetics; D008130:Lomustine / Q000009:adverse effects; D008173:Lung Diseases, Obstructive / Q000150:complications; D008223:Lymphoma / Q000150:complications / Q000188:drug therapy; D016403:Lymphoma, Large B-Cell, Diffuse / Q000150:complications* / Q000188:drug therapy; D008875:Middle Aged; D010976:Platelet Count; D011241:Prednisone / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D001761:Bleomycin; D014750:Vincristine; D008130:Lomustine; D004317:Doxorubicin; D003520:Cyclophosphamide; D011241:Prednisone